News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
KANEKO YASUNORI
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
06/16/2023 |
4
| KANEKO YASUNORI (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Granted 6,800 shares
@ $0 Granted 19,500 options to buy
@ $19.6, valued at
$382.2k
|
|
06/16/2022 |
4
| KANEKO YASUNORI (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Granted 4,100 shares
@ $0 Granted 16,800 options to buy
@ $20.62, valued at
$346.4k
|
|
06/07/2021 |
4
| KANEKO YASUNORI (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Granted 3,000 shares
@ $0 Granted 14,100 options to buy
@ $24.79, valued at
$349.5k
|
|
04/26/2021 |
4
| KANEKO YASUNORI (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Bought 4,133 shares
@ $31.37, valued at
$129.7k
|
|
06/08/2020 |
4
| KANEKO YASUNORI (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Granted 3,000 shares
@ $0 Granted 14,000 options to buy
@ $30.05, valued at
$420.7k
Exercised 35,000 options to buy
@ $7.99, valued at
$279.7k
|
|
06/10/2019 |
4
| KANEKO YASUNORI (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Granted 35,000 options to buy
@ $7.99, valued at
$279.7k
|
|
10/19/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/03/2018 |
4
| Skyline Venture Partners V LP (10% Owner) has filed a Form 4 on SUTRO BIOPHARMA INC
Txns:
| Converted 925,578 shares
@ $0 Converted 520,264 shares
@ $0 Converted 514,211 shares
@ $0 Converted 25,015,635 preferred shares
@ $0 Converted 12,846,023 preferred shares
@ $0 Converted 18,698,578 preferred shares
@ $0 |
|
03/19/2018 |
4
| KANEKO YASUNORI (Director) has filed a Form 4 on Arcus Biosciences, Inc.
Txns:
| Converted 505,050 shares
@ $0 Converted 252,524 shares
@ $0 Converted 33,818 shares
@ $0 Converted 505,050 convertible preferred
@ $0 Converted 252,524 convertible preferred
@ $0 Converted 31,253 convertible preferred
@ $0 Converted 2,565 convertible preferred
@ $0 |
|
12/07/2017 |
4
| KANEKO YASUNORI (10% Owner) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC
Txns:
| Disposed of 800,000 shares
@ $0 Acquired 270 shares
@ $0 |
|
05/13/2015 |
4
| Skyline Venture Partners V LP (10% Owner) has filed a Form 4 on COLLEGIUM PHARMACEUTICAL, INC
Txns:
| Converted 1,552,795 shares
@ $0 Converted 382,323 shares
@ $0 Converted 864,798 shares
@ $0 Bought 150,000 shares
@ $12, valued at
$1.8M
Converted 10,714,286 convertible preferred
@ $0 Converted 2,638,030 convertible preferred
@ $0 Converted 5,881,724 convertible preferred
@ $0 |
|
02/24/2015 |
4
| Skyline Venture Partners V LP (former 10% holder) has filed a Form 4 on Dicerna Pharmaceuticals Inc
Txns:
| Sold 37,532 shares
@ $26.02, valued at
$976.6k
|
|
10/29/2014 |
4
| Skyline Venture Partners Qualified Purchaser Fund IV L P (10% Owner) has filed a Form 4 on PROTEON THERAPEUTICS INC
Txns:
| Bought 200,000 shares
@ $10, valued at
$2M
Converted 1,167,208 shares
@ $0 Sold 56,038 shares
@ $10, valued at
$560.4k
Converted 5,000,000 convertible preferred
@ $0 Converted 2,341,664 convertible preferred
@ $0 Converted 2,173,913 convertible preferred
@ $0 Converted 2,436,437 convertible preferred
@ $0 Converted 3,932,747 convertible preferred
@ $0 Exercised (in-or-at-the-money) 121,760 warrants
@ $4.6023, valued at
$560.4k
Disposed of 1,389,064 options to buy
@ $0 |
|
03/14/2014 |
4
| Skyline Venture Partners Qualified Purchaser Fund IV L P (10% Owner) has filed a Form 4 on TETRAPHASE PHARMACEUTICALS INC
Txns:
| Disposed of 300,000 shares
@ $0 Acquired 4,493 shares
@ $0 |
|
03/11/2014 |
4
| Skyline Venture Partners Qualified Purchaser Fund IV L P (Former 10% Holder) has filed a Form 4 on ACELRX PHARMACEUTICALS INC
Txns:
| Disposed of 1,300,000 shares
@ $0 |
|
02/21/2014 |
4
| Skyline Venture Partners Qualified Purchaser Fund IV L P (10% Owner) has filed a Form 4 on CONCERT PHARMACEUTICALS, INC.
Txns:
| Converted 389,380 shares
@ $0 Converted 530,974 shares
@ $0 Converted 106,194 shares
@ $0 Bought 150,000 shares
@ $14, valued at
$2.1M
Converted 2,200,000 convertible preferred
@ $0 Converted 3,000,000 convertible preferred
@ $0 Converted 600,000 convertible preferred
@ $0 |
|
02/05/2014 |
4
| Skyline Venture Partners V LP (10% Owner) has filed a Form 4 on Dicerna Pharmaceuticals Inc
Txns:
| Converted 312,000 shares
@ $0 Converted 179,322 shares
@ $0 Converted 1,043,429 shares
@ $0 Bought 200,000 shares
@ $15, valued at
$3M
Converted 312,000 preferred shares
@ $0 Converted 179,322 preferred shares
@ $0 Converted 1,043,429 preferred shares
@ $0 Converted 755 warrants
@ $250, valued at
$188.8k
Converted 21,697 options to buy
@ $7, valued at
$151.9k
Converted 21,697 warrants
@ $7, valued at
$151.9k
|
|
03/27/2013 |
4
| Skyline Venture Partners Qualified Purchaser Fund IV L P (10% Owner) has filed a Form 4 on TETRAPHASE PHARMACEUTICALS INC
Txns:
| Converted 72,069 shares
@ $0 Converted 94,003 shares
@ $0 Converted 393,863 shares
@ $0 Converted 938,853 shares
@ $0 Bought 681,012 shares
@ $7, valued at
$4.8M
Converted 2,090,000 options to buy
@ $0 Converted 2,726,086 options to buy
@ $0 Converted 11,422,045 options to buy
@ $0 Converted 27,226,760 options to buy
@ $0 |
|
05/31/2012 |
4
| Skyline Venture Partners Qualified Purchaser Fund IV L P (10% Owner) has filed a Form 4 on ACELRX PHARMACEUTICALS INC
Txns:
| Bought 284,698 shares
@ $3.4, valued at
$968k
Bought 256,228 options to buy
@ $3.4, valued at
$871.2k
|
|
02/18/2011 |
4
| Skyline Venture Partners Qualified Purchaser Fund IV L P (10% Owner) has filed a Form 4 on ACELRX PHARMACEUTICALS INC
Txns:
| Converted 682,904 shares
@ $0 Converted 468,664 shares
@ $0 Converted 915,798 shares
@ $0 Converted 554,685 shares
@ $0 Converted 29,241 shares
@ $0 Bought 1,235,943 shares
@ $5, valued at
$6.2M
Converted 500,000 convertible preferred
@ $0 Converted 312,500 convertible preferred
@ $0 Converted 915,798 convertible preferred
@ $0 Converted convertible notes
@ $0 Exercised (in-or-at-the-money) 125,386 options to buy
@ $0 |
|
02/27/2009 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
|
|